SLC5A2 and heart failure: Moreover, in the large, multinational CVD-REAL study, treatment with an SGLT2 inhibitor was associated with lower rates of hospitalization for heart failure and death, compared with other glucose lowering drugs, implying CV benefits from SGLT2 inhibitor usage (7).